Skip to content
Evigrade
MajorNon-steroidal anti-inflammatory drug, oxicam×Calcineurin inhibitor (immunosuppressant)

Updated · Methodology

Mechanism

Tacrolimus can impair renal function on its own. Drugs with known nephrotoxic or neurotoxic effects, including non-steroidal anti-inflammatory drugs (NSAIDs), may potentiate these effects of tacrolimus (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Lornoxicam is an NSAID. According to its SmPC, lornoxicam given with tacrolimus increases the risk of nephrotoxicity because less prostacyclin is formed in the kidney (lornoxicam SmPC, AEMPS). In renal impairment, renal blood flow depends on renal prostaglandins (lornoxicam SmPC, AEMPS). Tacrolimus is more than 98.8% bound to plasma proteins and lornoxicam 99%. The tacrolimus SmPC asks prescribers to consider possible interactions with other highly protein-bound drugs, including NSAIDs (AEMPS).

Symptoms

Tacrolimus very commonly impairs renal function and causes hyperkalaemia. Common reactions include oliguria and renal failure, including acute renal failure (tacrolimus summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acute renal impairment from tacrolimus toxicity can show as high serum creatinine, hyperkalaemia, reduced urea excretion and hyperuricaemia, and is usually reversible (tacrolimus label, US Food and Drug Administration, FDA). With lornoxicam, raised blood creatinine and urea nitrogen are rare. Very rarely it can cause acute renal failure in people with pre-existing renal impairment. The lornoxicam SmPC links nephritis and nephritic syndrome to non-steroidal anti-inflammatory drugs as a class effect (lornoxicam SmPC, AEMPS).

Management

The combination is not contraindicated. The tacrolimus summary of product characteristics (SmPC) recommends avoiding tacrolimus with drugs that have known nephrotoxic effects and explicitly lists non-steroidal anti-inflammatory drugs (NSAIDs) among them. Lornoxicam belongs to this class (tacrolimus SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the combination cannot be avoided, closely monitor tacrolimus trough blood levels, renal function and other adverse effects. Adjust the tacrolimus dose if needed, and consider reducing it if nephrotoxicity occurs (AEMPS). Monitor renal function carefully when lornoxicam and tacrolimus are taken together (lornoxicam SmPC, AEMPS). The US tacrolimus label says to monitor renal function and tacrolimus blood levels when tacrolimus is combined with other known nephrotoxic drugs. During concurrent use, adjust the dose of tacrolimus, the other drug or both (tacrolimus label, US Food and Drug Administration, FDA). In mild (serum creatinine 150–300 µmol/L) and moderate (300–700 µmol/L) renal impairment, give lornoxicam with caution and only after carefully weighing risks and benefits. Stop it if renal function worsens during treatment (lornoxicam SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Tacrolimus